Liberate Bio’s CAR-M cell therapy almost completely depleted B-cells in a nonhuman primate study, the company said.

Moving Away From Standard Induction in Newly Diagnosed Acute Myeloid Leukemia As of April 2025, four CD19-directed chimeric antigen receptor (CAR)-T therapies and three CD20-targeting bispecific ...

Naïve B cells exit quiescence and enter a proliferative state upon activation, ultimately differentiating into antibody-secreting or memory B cells. Toll-like receptor (TLR) ligands, such as ...

Please provide your email address to receive an email when new articles are posted on . A “complete eradication” of B cells with chimeric antigen receptor T-cell therapy is responsible for the ...

SOUTH SAN FRANCISCO, Calif., and NEW HAVEN, Conn., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Simcha Therapeutics (“Simcha”), a clinical-stage ...

JADE201 builds on clinical proof-of-concept for BAFF-R targeting, adding half-life extension technology to provide extended receptor occupancy with the goal of delivering deeper, more durable B cell ...

WATERTOWN, Mass.--(BUSINESS WIRE)--Seismic Therapeutic, Inc., the machine learning immunology company, today announced the presentation of preclinical data for its immunoglobulin E (IgE) protease, ...

A new artificial intelligence (AI) tool can simultaneously assess blood samples for infections, autoimmune diseases, and vaccine responses, according to a new study. The algorithm analyzed genes ...